Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study
BackgroundThe oral, selective, and potent small molecule cyclin-dependent kinases (CDK) 4/6 inhibitor (CDK4/6i) abemaciclib has demonstrated efficacy in advanced breast cancer and high-risk early breast cancer. This Phase 1b study evaluated the safety, tolerability, pharmacokinetics, and antitumor a...
保存先:
| 主要な著者: | , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2025-03-01
|
| シリーズ: | Frontiers in Oncology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1555921/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|